Independence Blue Cross to Cover MDxHealth Prostate Cancer Test
News Sep 29, 2016
MDxHealth SA has announced that Independence Blue Cross (Independence) has issued a positive medical coverage policy decision for the ConfirmMDx® for Prostate Cancer test. Independence Blue Cross is the leading health insurance organization in southeastern Pennsylvania. With its affiliates, Independence serves nearly 8.5 million people in 32 states and the District of Columbia, including more than 2.5 million in the region.
Independence is one of the 38 independent companies that form the Blue Cross and Blue Shield Association (BCBSA) that collectively cover more than 98 million people or 1 in 3 Americans. This positive policy decision for their commercial and Medicare lives represents the first BCBSA plan to establish coverage for ConfirmMDx for Prostate Cancer.
"This positive coverage decision by Independence Blue Cross is a significant milestone as we work towards achieving nationwide payer adoption of our ConfirmMDx for Prostate Cancer test," stated Dr. Jan Groen, CEO of MDxHealth. "This decision demonstrates that our investment in clinical studies and our work with managed care organisations in the US continues to yield positive results."
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE